Date Name Title Filing Type Shares Traded Price Total Held
Dec 19, 2017
Director, President and CSO
Director, President and CSO Form 4 Bona fide gift 242,150 -- 486,820
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 240,000 $52.03 880,938
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 240,000 -- 158,079
Dec 16, 2014
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 240,000 -- 398,079
Dec 14, 2012
Director, EVP CSO Pres Regen Res Labs
Director, EVP CSO Pres Regen Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 239,063 -- 239,063
Dec 17, 2012
Director, EVP CSO Pres Regen Res Labs
Director, EVP CSO Pres Regen Res Labs Form 4 Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 230,350 $179.13 1,066,484
Jan 05, 2005
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 222,000 -- 356,332
Jun 24, 2021
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Bona fide gift 211,585 -- 213,693
Jun 24, 2021
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Bona fide gift 211,585 -- --
Dec 13, 2013
Director, Pres Regeneron Labs
Director, Pres Regeneron Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 203,204 -- 203,204

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.